A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases
Studies evaluating xanthine oxidoreductase (XOR) activities in comprehensive liver diseases are scarce, and different etiologies have previously been combined in groups for comparison. To accurately evaluate XOR activities in liver diseases, the plasma XOR activities in etiology-based comprehensive...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/5/1445 |
| _version_ | 1797600933832556544 |
|---|---|
| author | Ken Sato Atsushi Naganuma Tamon Nagashima Yosuke Arai Yuka Mikami Yuka Nakajima Yuki Kanayama Tatsuma Murakami Sanae Uehara Daisuke Uehara Yuichi Yamazaki Takayo Murase Takashi Nakamura Toshio Uraoka |
| author_facet | Ken Sato Atsushi Naganuma Tamon Nagashima Yosuke Arai Yuka Mikami Yuka Nakajima Yuki Kanayama Tatsuma Murakami Sanae Uehara Daisuke Uehara Yuichi Yamazaki Takayo Murase Takashi Nakamura Toshio Uraoka |
| author_sort | Ken Sato |
| collection | DOAJ |
| description | Studies evaluating xanthine oxidoreductase (XOR) activities in comprehensive liver diseases are scarce, and different etiologies have previously been combined in groups for comparison. To accurately evaluate XOR activities in liver diseases, the plasma XOR activities in etiology-based comprehensive liver diseases were measured using a novel, sensitive, and accurate assay that is a combination of liquid chromatography and triple quadrupole mass spectrometry to detect [<sup>13</sup>C<sub>2</sub>, <sup>15</sup>N<sub>2</sub>]uric acid using [<sup>13</sup>C<sub>2</sub>, <sup>15</sup>N<sub>2</sub>]xanthine as a substrate. We also mainly evaluated the association between the plasma XOR activities and parameters of liver tests, purine metabolism-associated markers, oxidative stress markers, and an inflammation marker. In total, 329 patients and 32 controls were enrolled in our study. Plasma XOR activities were generally increased in liver diseases, especially in the active phase, such as in patients with hepatitis C virus RNA positivity, those with abnormal alanine transaminase (ALT) levels in autoimmune liver diseases, and uncured hepatocellular carcinoma patients. Plasma XOR activities were numerically highest in patients with acute hepatitis B. Plasma XOR activities were closely correlated with parameters of liver tests, especially serum ALT levels, regardless of etiology and plasma xanthine levels. Our results indicated that plasma XOR activity might reflect the active phase in various liver diseases. |
| first_indexed | 2024-03-11T03:54:50Z |
| format | Article |
| id | doaj.art-87542a799eff4f30be8eb141004079f8 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T03:54:50Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-87542a799eff4f30be8eb141004079f82023-11-18T00:37:13ZengMDPI AGBiomedicines2227-90592023-05-01115144510.3390/biomedicines11051445A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver DiseasesKen Sato0Atsushi Naganuma1Tamon Nagashima2Yosuke Arai3Yuka Mikami4Yuka Nakajima5Yuki Kanayama6Tatsuma Murakami7Sanae Uehara8Daisuke Uehara9Yuichi Yamazaki10Takayo Murase11Takashi Nakamura12Toshio Uraoka13Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, JapanDepartment of Gastroenterology, National Hospital Organization Shibukawa Medical Center, Shibukawa 377-0204, JapanDepartment of Gastroenterology, National Hospital Organization Shibukawa Medical Center, Shibukawa 377-0204, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki 370-0829, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanMie Research Park, Sanwa Kagaku Kenkyusho, Inabe 511-0406, JapanMie Research Park, Sanwa Kagaku Kenkyusho, Inabe 511-0406, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi 371-8511, JapanStudies evaluating xanthine oxidoreductase (XOR) activities in comprehensive liver diseases are scarce, and different etiologies have previously been combined in groups for comparison. To accurately evaluate XOR activities in liver diseases, the plasma XOR activities in etiology-based comprehensive liver diseases were measured using a novel, sensitive, and accurate assay that is a combination of liquid chromatography and triple quadrupole mass spectrometry to detect [<sup>13</sup>C<sub>2</sub>, <sup>15</sup>N<sub>2</sub>]uric acid using [<sup>13</sup>C<sub>2</sub>, <sup>15</sup>N<sub>2</sub>]xanthine as a substrate. We also mainly evaluated the association between the plasma XOR activities and parameters of liver tests, purine metabolism-associated markers, oxidative stress markers, and an inflammation marker. In total, 329 patients and 32 controls were enrolled in our study. Plasma XOR activities were generally increased in liver diseases, especially in the active phase, such as in patients with hepatitis C virus RNA positivity, those with abnormal alanine transaminase (ALT) levels in autoimmune liver diseases, and uncured hepatocellular carcinoma patients. Plasma XOR activities were numerically highest in patients with acute hepatitis B. Plasma XOR activities were closely correlated with parameters of liver tests, especially serum ALT levels, regardless of etiology and plasma xanthine levels. Our results indicated that plasma XOR activity might reflect the active phase in various liver diseases.https://www.mdpi.com/2227-9059/11/5/1445xanthine oxidoreductaseliver diseaseetiologyalanine aminotransferasexanthineoxidative stress |
| spellingShingle | Ken Sato Atsushi Naganuma Tamon Nagashima Yosuke Arai Yuka Mikami Yuka Nakajima Yuki Kanayama Tatsuma Murakami Sanae Uehara Daisuke Uehara Yuichi Yamazaki Takayo Murase Takashi Nakamura Toshio Uraoka A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases Biomedicines xanthine oxidoreductase liver disease etiology alanine aminotransferase xanthine oxidative stress |
| title | A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases |
| title_full | A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases |
| title_fullStr | A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases |
| title_full_unstemmed | A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases |
| title_short | A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases |
| title_sort | newly developed method based xanthine oxidoreductase activities in various human liver diseases |
| topic | xanthine oxidoreductase liver disease etiology alanine aminotransferase xanthine oxidative stress |
| url | https://www.mdpi.com/2227-9059/11/5/1445 |
| work_keys_str_mv | AT kensato anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT atsushinaganuma anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT tamonnagashima anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yosukearai anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yukamikami anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yukanakajima anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yukikanayama anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT tatsumamurakami anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT sanaeuehara anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT daisukeuehara anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yuichiyamazaki anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT takayomurase anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT takashinakamura anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT toshiouraoka anewlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT kensato newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT atsushinaganuma newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT tamonnagashima newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yosukearai newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yukamikami newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yukanakajima newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yukikanayama newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT tatsumamurakami newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT sanaeuehara newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT daisukeuehara newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT yuichiyamazaki newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT takayomurase newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT takashinakamura newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases AT toshiouraoka newlydevelopedmethodbasedxanthineoxidoreductaseactivitiesinvarioushumanliverdiseases |